Figure 3
Tertiapin-Q effect in Cav1.3−/− SND mice. (A) Representative samples of telemetric ECG recordings from Cav1.3−/− mice before (left) and after (right) tertiapin-Q (Tert) injection; arrow indicates AVBII. B: PP rate increase following injection of tertiapin-Q. C: PR interval duration before (filled red circle) and after (horizontally red-striped circle) injection of 5 mg/kg tertiapin-Q. Statistics (B,C): paired t-test Number of AVBII (D) and SAN pause (E) counted in Cav1.3−/− animals in the absence (filled red circle) and in the presence (horizontally red-striped circle) of 5 mg/kg tertiapin-Q. Statistics (D,E): Wilcoxon test. Dot-plots of RR versus PR intervals measured in Cav1.3−/− mice, and relative linear regression line, in control conditions (F) and after injection of 5 mg/kg tertiapin-Q (G). (H) r-Spearman correlation coefficients calculated in control condition (full red circle) and after (horizontally red-striped circle) of 5 mg/kg tertiapin-Q. Statistics: Wilcoxon test. (I) Angular coefficients of the regression line between the RR and the respective PR intervals before (filled red circle), after injection of the peptide in Cav1.3−/− (horizontally red-striped bar) and after injection of the peptide in WT (horizontally black-striped circle) mice. Statistics: Kruskal-Wallis test followed by multiple comparison Dunn’s test. Error bars define the s.e.m.
